CHINOOK THERAPEUTICS, INC.
KDNY evidence brief
What we can confirm
- BioSniper Score:
- 7.2 / 10
- Lead Asset:
- atrasentan (Phase 3)
What it means
What to watch
Prepared research question
What matters most for KDNY—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 3 pipeline candidates for CHINOOK THERAPEUTICS, INC..
Run CHINOOK THERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CHINOOK THERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Frequently asked questions
What is CHINOOK THERAPEUTICS, INC.'s lead drug candidate?
CHINOOK THERAPEUTICS, INC.'s most advanced tracked candidate is atrasentan (Phase 3) for IgA nephropathy (IgAN) and proteinuric glomerular diseases.
Who is the CEO of CHINOOK THERAPEUTICS, INC.?
Eric Dobmeier is the chief executive officer of CHINOOK THERAPEUTICS, INC. (KDNY).
What therapeutic areas does CHINOOK THERAPEUTICS, INC. focus on?
CHINOOK THERAPEUTICS, INC. develops therapies across Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.